178 related articles for article (PubMed ID: 6508821)
1. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
White JC; Hines LH
Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
[TBL] [Abstract][Full Text] [Related]
2. Cooperative binding of the bisubstrate analog N-(phosphonacetyl)-L-aspartate to aspartate transcarbamoylase and the heterotropic effects of ATP and CTP.
Newell JO; Markby DW; Schachman HK
J Biol Chem; 1989 Feb; 264(5):2476-81. PubMed ID: 2644262
[TBL] [Abstract][Full Text] [Related]
3. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis.
White JC; Hines LH
Cancer Res; 1984 Feb; 44(2):507-13. PubMed ID: 6692357
[TBL] [Abstract][Full Text] [Related]
4. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
[TBL] [Abstract][Full Text] [Related]
7. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
[TBL] [Abstract][Full Text] [Related]
8. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
Erlichman C; Strong JM; Chabner BA
Cancer Res; 1980 Jun; 40(6):1902-6. PubMed ID: 7371023
[TBL] [Abstract][Full Text] [Related]
9. 13C isotope effect studies of Escherichia coli aspartate transcarbamylase in the presence of the bisubstrate analog N-(phosphonoacetyl)-L-aspartate.
Parmentier LE; O'Leary MH; Schachman HK; Cleland WW
Biochemistry; 1992 Jul; 31(28):6598-602. PubMed ID: 1633172
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of the interaction of N-(phosphonacetyl)-L-aspartate with the catalytic subunit of aspartate transcarbamoylase. A slow conformational change subsequent to binding.
Cohen RE; Schachman HK
J Biol Chem; 1986 Feb; 261(6):2623-31. PubMed ID: 3949739
[TBL] [Abstract][Full Text] [Related]
11. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
12. Aspartate transcarbamylase (ATCase) of Escherichia coli: a new crystalline R-state bound to PALA, or to product analogues citrate and phosphate.
Huang J; Lipscomb WN
Biochemistry; 2004 Jun; 43(21):6415-21. PubMed ID: 15157075
[TBL] [Abstract][Full Text] [Related]
13. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
[TBL] [Abstract][Full Text] [Related]
14. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
[TBL] [Abstract][Full Text] [Related]
15. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
Kensler TW; Jayaram HN; Cooney DA
J Biochem Biophys Methods; 1980; 2(1):29-35. PubMed ID: 6999068
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of new transition-state analogue inhibitors of aspartate transcarbamylase.
Farrington GK; Kumar A; Wedler FC
J Med Chem; 1985 Nov; 28(11):1668-73. PubMed ID: 4067992
[TBL] [Abstract][Full Text] [Related]
17. Aspartate transcarbamylase from the hyperthermophilic archaeon Pyrococcus abyssi: thermostability and 1.8A resolution crystal structure of the catalytic subunit complexed with the bisubstrate analogue N-phosphonacetyl-L-aspartate.
Van Boxstael S; Cunin R; Khan S; Maes D
J Mol Biol; 2003 Feb; 326(1):203-16. PubMed ID: 12547202
[TBL] [Abstract][Full Text] [Related]
18. 2.5 A structure of aspartate carbamoyltransferase complexed with the bisubstrate analog N-(phosphonacetyl)-L-aspartate.
Krause KL; Volz KW; Lipscomb WN
J Mol Biol; 1987 Feb; 193(3):527-53. PubMed ID: 3586030
[TBL] [Abstract][Full Text] [Related]
19. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
[TBL] [Abstract][Full Text] [Related]
20. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
